Your session is about to expire
← Back to Search
Other
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 36
Summary
This trial is testing a new drug called LY3502970 to see if it can help people who are overweight or have obesity lose weight.
Eligible Conditions
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 36
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 36
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change From Baseline in BMI in LY3502970 and Placebo
Change From Baseline in Body Weight in LY3502970 and Placebo
Change From Baseline in Waist Circumference in LY3502970 and Placebo
+3 moreSide effects data
From 2022 Phase 2 trial • 383 Patients • NCT0504871938%
Nausea
21%
Vomiting
16%
Diarrhoea
13%
Constipation
9%
Fatigue
9%
Covid-19
9%
Lipase increased
7%
Dyspepsia
7%
Gastrooesophageal reflux disease
5%
Palpitations
5%
Abdominal distension
5%
Decreased appetite
4%
Eructation
4%
Weight decreased
4%
Arthralgia
4%
Headache
4%
Urticaria
2%
Abdominal pain upper
2%
Upper respiratory tract infection
2%
Muscle spasms
2%
Dizziness
2%
Hypertension
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3502970
24 mg LY3502970
36 mg LY3502970 - 1
36 mg LY3502970 - 2
45 mg LY3502970 - 1
Placebo
3 mg LY3502970
45 mg LY3502970 - 2
1.5 mg Dulaglutide
Trial Design
7Treatment groups
Experimental Treatment
Placebo Group
Group I: 45 mg-2 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Group II: 45 mg-1 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Group III: 36 mg-2 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Group IV: 36 mg-1 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Group V: 24 mg LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
Group VI: 12 milligram (mg) LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
Group VII: PlaceboPlacebo Group1 Intervention
Participants received placebo administered orally once daily until 36 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1300
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,112 Total Patients Enrolled
69 Trials studying Obesity
46,815 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company